Pacer Advisors Inc. Grows Holdings in Johnson & Johnson (NYSE:JNJ)

Pacer Advisors Inc. grew its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 11.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 285,486 shares of the company’s stock after buying an additional 30,395 shares during the quarter. Johnson & Johnson accounts for about 0.8% of Pacer Advisors Inc.’s investment portfolio, making the stock its 12th largest holding. Pacer Advisors Inc.’s holdings in Johnson & Johnson were worth $36,936,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in Johnson & Johnson by 0.7% during the second quarter. Vanguard Group Inc. now owns 225,158,988 shares of the company’s stock worth $31,360,143,000 after purchasing an additional 1,627,370 shares during the last quarter. Phocas Financial Corp. lifted its stake in Johnson & Johnson by 999,928.6% during the second quarter. Phocas Financial Corp. now owns 125,173,583 shares of the company’s stock worth $174,342,000 after purchasing an additional 125,161,066 shares during the last quarter. Northern Trust Corp lifted its stake in Johnson & Johnson by 0.9% during the second quarter. Northern Trust Corp now owns 35,255,462 shares of the company’s stock worth $4,910,381,000 after purchasing an additional 313,073 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Johnson & Johnson by 11.9% during the second quarter. Price T Rowe Associates Inc. MD now owns 20,791,713 shares of the company’s stock worth $2,895,870,000 after purchasing an additional 2,204,757 shares during the last quarter. Finally, Morgan Stanley lifted its stake in Johnson & Johnson by 0.6% during the second quarter. Morgan Stanley now owns 19,995,067 shares of the company’s stock worth $2,784,913,000 after purchasing an additional 122,033 shares during the last quarter. Institutional investors own 72.01% of the company’s stock.

Several brokerages have weighed in on JNJ. Raymond James dropped their target price on Johnson & Johnson from $147.00 to $146.00 and set an “outperform” rating on the stock in a research report on Wednesday, July 17th. Morgan Stanley reaffirmed an “equal weight” rating and issued a $145.00 target price on shares of Johnson & Johnson in a research report on Tuesday, August 27th. Bank of America reaffirmed a “hold” rating and issued a $150.00 target price on shares of Johnson & Johnson in a research report on Tuesday, July 16th. Goldman Sachs Group set a $169.00 target price on Johnson & Johnson and gave the stock a “buy” rating in a research report on Tuesday, August 27th. Finally, Royal Bank of Canada reaffirmed a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, July 16th. Five investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Johnson & Johnson has an average rating of “Buy” and a consensus price target of $151.00.

NYSE JNJ traded up $3.15 during trading hours on Friday, hitting $132.21. The company had a trading volume of 1,312,058 shares, compared to its average volume of 6,702,304. Johnson & Johnson has a fifty-two week low of $121.00 and a fifty-two week high of $148.99. The company has a quick ratio of 1.04, a current ratio of 1.33 and a debt-to-equity ratio of 0.46. The business has a fifty day simple moving average of $129.92 and a 200-day simple moving average of $135.00. The firm has a market cap of $347.95 billion, a P/E ratio of 16.16, a price-to-earnings-growth ratio of 2.22 and a beta of 0.69.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, July 16th. The company reported $2.58 EPS for the quarter, beating analysts’ consensus estimates of $2.42 by $0.16. The company had revenue of $20.56 billion for the quarter, compared to analyst estimates of $20.39 billion. Johnson & Johnson had a return on equity of 38.63% and a net margin of 20.08%. The company’s quarterly revenue was down 1.3% compared to the same quarter last year. During the same period last year, the company earned $2.10 earnings per share. Equities analysts forecast that Johnson & Johnson will post 8.59 EPS for the current fiscal year.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Read More: What causes a stock to be most active?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.